Iridex trims full-year sales outlook as European and Asian laser demand softens
The US ophthalmic laser maker posted a quarterly revenue fall of $2.3M, remains loss-making despite a better gross margin, and is reassessing its product range and factory footprint.
Iridex, which sells laser systems and consumable probes for glaucoma and retinal disease, now expects 2026 revenue of $46M to $48M, after a third quarter in which sales fell well short of the prior-year level. Revenue for the period ended 3 October was $10.2M, compared with $12.5M a year earlier, a drop of nearly a fifth. The company reported the results on 17 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Company's press release (SEC filing): Iridex Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.